Peptides for Body Recomposition & Lean Mass Optimization

How peptide Targets Peptides for Body Recomposition

Tesamorelin is the most evidence-based peptide for recomposition-relevant endpoints. As a growth hormone-releasing hormone (GHRH) analog, it specifically stimulates pituitary GH secretion while maintaining physiological pulsatility — unlike exogenous GH, which bypasses feedback regulation. Its Phase 3 clinical program demonstrated approximately 15% reduction in visceral adipose tissue (the metabolically active abdominal fat depot) with preservation of lean mass in HIV-associated lipodystrophy. Subsequent studies in non-HIV populations with abdominal adiposity show similar visceral fat reduction alongside improvements in trunk fat and inflammatory markers. Tesamorelin's specificity for visceral fat (rather than total body weight reduction) makes it mechanistically distinct from GLP-1 agonists, which produce broader weight loss that includes lean mass.

CJC-1295 combined with ipamorelin represents the growth hormone secretagogue (GHS) approach to recomposition. CJC-1295 (a GHRH analog with extended half-life via Drug Affinity Complex technology) amplifies GH pulse amplitude, while ipamorelin (a selective ghrelin receptor agonist) increases GH pulse frequency. The combination aims to maximize GH output without supraphysiological spikes, supporting lipolysis (particularly during fasting and exercise), protein synthesis, and connective tissue repair. The recomposition logic is that optimized GH levels create a metabolic environment favoring fat oxidation for energy while directing amino acids toward muscle protein synthesis. Clinical evidence for this specific combination is limited to small studies and practitioner-reported outcomes — it lacks the Phase 3 program of tesamorelin.

Ibutamoren (MK-677) is an oral, non-peptide growth hormone secretagogue that activates the ghrelin receptor. Its inclusion in recomposition protocols is based on convenience (oral dosing), sustained GH elevation (it increases GH secretion for up to 24 hours after a single dose), and consistent effects on lean mass. In clinical studies of elderly and GH-deficient populations, ibutamoren increased fat-free mass by 1-2 kg over 12 months and improved nitrogen balance. The major trade-off for recomposition goals is its appetite-stimulating effect (a direct consequence of ghrelin receptor agonism), which can complicate the caloric management needed for simultaneous fat loss. Water retention from increased GH is another consideration that can mask true body composition changes on the scale.

Semaglutide enters the recomposition conversation from the opposite direction — as a potent fat-loss agent that raises the question of muscle preservation. In weight-loss trials, approximately 30-40% of weight lost on semaglutide is lean mass, consistent with any large caloric deficit. For recomposition specifically, semaglutide is relevant when the primary barrier to recomposition is excess adiposity that prevents effective training and nutrient partitioning. Some practitioners combine GLP-1 agonists with GH secretagogues, theoretically using the GLP-1 for appetite control and fat loss while using GHS peptides to provide an anabolic signal that preserves lean mass. This combination strategy has mechanistic logic but no controlled clinical data specifically evaluating recomposition endpoints.